Another COVID-19 vaccine candidate recently entered the races. The difference – this one is a live attenuated (weakened) virus expressing the coronavirus’s signature spike protein on its surface. And it’s delivered nasally, not a shot.
“COVID-19 vaccine development will be more of a marathon than a sprint,” Martin Moore, Ph.D., co-founder and CEO of Meissa Vaccines, told BioSpace. “A live attenuated vaccine may not be first-in-class, but their historically high efficacy could make it the best-in-class.”
Moore spoke with BioSpace about live attenuated vaccines, interim data from their RSV vaccine candidate, and how they are building on their RSV vaccine platform to create a COVID-19 vaccine.
Read the full article on BioSpace.
Opmerkingen